APA

Beydoun A., Fischer J., Labar D. R., Harden C., Cantrell D., Uthman B. M., Sackellares J. C., Abou-Khalil B., Ramsay R. E., Hayes A., Greiner M., Garofalo E. & Pierce M. (19971010). Gabapentin monotherapy: II. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 82/83. : Neurology.

Chicago

Beydoun A, Fischer J, Labar D R, Harden C, Cantrell D, Uthman B M, Sackellares J C, Abou-Khalil B, Ramsay R E, Hayes A, Greiner M, Garofalo E and Pierce M. 19971010. Gabapentin monotherapy: II. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 82/83. : Neurology.

Harvard

Beydoun A., Fischer J., Labar D. R., Harden C., Cantrell D., Uthman B. M., Sackellares J. C., Abou-Khalil B., Ramsay R. E., Hayes A., Greiner M., Garofalo E. and Pierce M. (19971010). Gabapentin monotherapy: II. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 82/83. : Neurology.

MLA

Beydoun A, Fischer J, Labar D R, Harden C, Cantrell D, Uthman B M, Sackellares J C, Abou-Khalil B, Ramsay R E, Hayes A, Greiner M, Garofalo E and Pierce M. Gabapentin monotherapy: II. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 82/83. : Neurology. 19971010.